

# Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/CE875B1C3028EN.html>

Date: August 2022

Pages: 92

Price: US\$ 3,500.00 (Single User License)

ID: CE875B1C3028EN

## Abstracts

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Factor XI or plasma thromboplastin antecedent is the zymogen form of factor X<sub>II</sub>. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Inhibitors of factor X<sub>II</sub>a include protein Z-dependent protease inhibitor.

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) pipeline Target constitutes close to 30 molecules. Out of which approximately 29 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 8, 7, 2, 10 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Hematological Disorders, Genito Urinary System And Sex Hormones, Infectious Disease, Central Nervous System and Immunology which include indications Thrombosis, Venous Thromboembolism, Bleeding And Clotting Disorders, Arterial Thrombosis, End-Stage Kidney Disease (End-

Stage Renal Disease or ESRD), Thromboembolic Disease, Atrial Fibrillation, Deep Vein Thrombosis (DVT), Hemophilia C (Factor XI Deficiency), Venous (Vein) Thrombosis, Acute Ischemic Stroke, Blood Coagulation, Coronavirus Disease 2019 (COVID-19), Inflammation, Ischemic Stroke, Myocardial Infarction, Neurology, Pulmonary Embolism, Sepsis, Stroke and Thromboembolism.

The latest report Coagulation Factor XI - Drugs In Development, 2022, outlays comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)

The report reviews Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics and enlists all their major and minor projects

The report assesses Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Coagulation

Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)  
development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) -  
Overview

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) -  
Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) -  
Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) -  
Companies Involved in Therapeutics Development

Alphamab Oncology

Anthos Therapeutics Inc

Aronora Inc

Bayer AG

Bio Products Laboratory Ltd

Bioxodes SA

Bristol-Myers Squibb Co

Cambryn Biologics LLC

China Resources Pharmaceutical Group Ltd

eXithera Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Jiangsu Hengrui Medicine Co Ltd

KLUS Pharma Inc

Merck & Co Inc

Mochida Pharmaceutical Co Ltd

Novartis AG

Ono Pharmaceutical Co Ltd

Regeneron Pharmaceuticals Inc

Shenzhen Salubris Pharmaceuticals Co Ltd

Sichuan Kelun Pharmaceutical Co Ltd

Sirnaomics Ltd

Suzhou Ribo Life Sciences Co Ltd

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) -  
Drug Profiles

7300 Series - Drug Profile

Product Description

Mechanism Of Action

A-186 - Drug Profile

Product Description

Mechanism Of Action

History of Events

A-336 - Drug Profile

Product Description

Mechanism Of Action

AB-023 - Drug Profile

Product Description

Mechanism Of Action

History of Events

abelacimab - Drug Profile

Product Description

Mechanism Of Action

History of Events

asundexian - Drug Profile

Product Description

Mechanism Of Action

History of Events

BMS-962212 - Drug Profile

Product Description

Mechanism Of Action

History of Events

BMS-986209 - Drug Profile

Product Description

Mechanism Of Action

History of Events

coagulation factor XI (human) - Drug Profile

Product Description

Mechanism Of Action

History of Events

coagulation factor XI (human) - Drug Profile

Product Description

Mechanism Of Action

History of Events

coagulation factor XI (human) - Drug Profile

Product Description

Mechanism Of Action

History of Events

EP-7041 - Drug Profile

Product Description

Mechanism Of Action

History of Events

fesomersen sodium - Drug Profile

Product Description

Mechanism Of Action

History of Events

IONIS-FXIRx - Drug Profile

Product Description

Mechanism Of Action

History of Events

Ir-CPI - Drug Profile

Product Description

Mechanism Of Action

History of Events

KN-060 - Drug Profile

Product Description

Mechanism Of Action

milvexian - Drug Profile

Product Description

Mechanism Of Action

History of Events

MK-2060 - Drug Profile

Product Description

Mechanism Of Action

History of Events

MR-1007 - Drug Profile

Product Description

Mechanism Of Action

History of Events

NIP-003 - Drug Profile

Product Description

Mechanism Of Action

ONO-7684 - Drug Profile

Product Description

Mechanism Of Action

History of Events

osocimab - Drug Profile

Product Description

Mechanism Of Action

History of Events

REGN-9933 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SAL-0104 - Drug Profile

Product Description

Mechanism Of Action

SHR-2285 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SKB-336 - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit Coagulation Factor XI for Bleeding and Clotting Disorders -  
Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit Factor XI for Bleeding And Clotting Disorders - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit Factor XIa for Arterial Thrombosis - Drug Profile

Product Description

Mechanism Of Action

History of Events

SR-059 - Drug Profile

Product Description



Mechanism Of Action

STP-122G - Drug Profile

Product Description

Mechanism Of Action

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) -  
Dormant Products

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) -  
Discontinued Products

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) -  
Product Development Milestones

Featured News & Press Releases

Aug 28, 2022: Late-breaking results from phase 2 AXIOMATIC-SSP study of Milvexian, an investigational oral factor XIa inhibitor, show favorable antithrombotic profile in combination with dual antiplatelet therapy

Aug 25, 2022: Anthos therapeutics launches second phase 3 clinical trial of its dual-acting Factor XI inhibitor, abelacimab

Aug 23, 2022: Merck receives fast track designation from the U.S. FDA for MK-2060, an investigational anticoagulant therapy

Aug 22, 2022: Bayer to present data from cardiovascular portfolio, including a late-breaking presentation from new phase IIb data from PACIFIC Trial program for the oral factor XIa Inhibitor asundexian

Jul 29, 2022: Ionis reports positive Phase IIb data of fesomersen for thrombosis

Jul 28, 2022: Phase 2b studies of investigational selective coagulation modulator osocimab in patients with advanced renal disease completed

Jul 13, 2022: Four new sets of pre-clinical data further expands the evidence supporting abelacimab

Jul 11, 2022: Anthos Therapeutics announces that abelacimab has received FDA fast track designation for the treatment of thrombosis associated with cancer

Jun 13, 2022: Anthos Therapeutics to host discussion with global experts on the promise of Factor XI Inhibition at the 2022 BIO International Convention

May 05, 2022: Abelacimab: first factor XI inhibitor to enroll patients in a phase 3 clinical trial

Apr 11, 2022: Announcement of Haisco on obtaining the drug clinical trial approval notice for HSK36273

Apr 03, 2022: Bayer presents positive results from first Phase 2b trial on safety of asundexian in patients with atrial fibrillation

Mar 29, 2022: Bayer to present data on Asundexian at the American College of Cardiology's 71st Annual Scientific Session

Feb 10, 2022: Bayer receives FDA Fast Track Designation for asundexian stroke

program

Jan 18, 2022: Haisco announces notice of acceptance for clinical trial application of HSK36273 for innovative drug injection

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Alphamab Oncology, 2022

Pipeline by Anthos Therapeutics Inc, 2022

Pipeline by Aronora Inc, 2022

Pipeline by Bayer AG, 2022

Pipeline by Bio Products Laboratory Ltd, 2022

Pipeline by Bioxodes SA, 2022

Pipeline by Bristol-Myers Squibb Co, 2022

Pipeline by Cambryn Biologics LLC, 2022

Pipeline by China Resources Pharmaceutical Group Ltd, 2022

Pipeline by eXithera Pharmaceuticals Inc, 2022

Pipeline by Ionis Pharmaceuticals Inc, 2022

Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Pipeline by KLUS Pharma Inc, 2022

Pipeline by Merck & Co Inc, 2022

Pipeline by Mochida Pharmaceutical Co Ltd, 2022

Pipeline by Novartis AG, 2022

Pipeline by Ono Pharmaceutical Co Ltd, 2022

Pipeline by Regeneron Pharmaceuticals Inc, 2022

Pipeline by Shenzhen Salubris Pharmaceuticals Co Ltd, 2022

Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2022

Pipeline by Sirnaomics Ltd, 2022

Pipeline by Suzhou Ribo Life Sciences Co Ltd, 2022

Dormant Projects, 2022

Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

## I would like to order

Product name: Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)  
Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule  
Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/CE875B1C3028EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer  
Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click  
button on product page <https://marketpublishers.com/r/CE875B1C3028EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form  
below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms  
& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970